Management of severe Raynaud's phenomenon

Journal of Clinical Rheumatology

Volumn 2, Issue 2, 1996, Pages 103-111

  Wigley, Fredrick M ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Calcium channel blockers; Prostaglandins; Raynaud's phenomenon; Sympathectomy

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; AMLODIPINE; AMPHETAMINE DERIVATIVE; ANTITHROMBOCYTIC AGENT; BLEOMYCIN; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CLONIDINE; CRYOGLOBULIN; DILTIAZEM; ENDOTHELIN 1; ERGOTAMINE; FELODIPINE; ILOPROST; INDORAMIN; ISRADIPINE; METHYLDOPA; MISOPROSTOL; NICARDIPINE; NIFEDIPINE; PHENOXYBENZAMINE; PHENTOLAMINE; PRAZOSIN; PROSTAGLANDIN; SEROTONIN RECEPTOR; UNINDEXED DRUG; VASODILATOR AGENT; VINBLASTINE; VINYL CHLORIDE;

ANTICOAGULATION; ARTICLE; BLOOD CLOT LYSIS; CLINICAL FEATURE; CLINICAL TRIAL; CRYOGLOBULINEMIA; FEEDBACK SYSTEM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAYNAUD PHENOMENON; SCLERODERMA; SYMPATHECTOMY; VASODILATATION;

EID: 0029934564     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/00124743-199604000-00009     Document Type: Article

References (58)

1. Maricq HR, Weinrich MC, Keil JE, LeRoy EC. Prevalence of Raynaud phenomenon in the general population. A preliminary study by questionnaire. J Chron Dis 1986;9:423-427.
2. Rodnan GP, Myerowitz RL, Justh GO. Morphologic changes in the digital arteries of patients with progressive systemic sclerosis (Scleroderma) and Raynaud phenomenon. Medicine 1980;59:353-408.
3. Freedman RR, Ianni P, Wenig P. Behavioral Treatment of Raynaud's Phenomenon in Scleroderma. J Behavioral Med 1984;7:343-353.
4. Rodeheffer R, Rommer J, Wigley FM, Smith C. A randomized double blind trial of nifedipine in the treatment of digital Raynaud's phenomenon. N Engl J Med 1983;15:880-683.
5. Malamet R, Ettinger WH, Wise RA, Wigley FM. Nifedipine in the treatment of Raynaud's phenomenon: evidence for inhibition of platelet activation. Am J Med 1983;78:602-608.
6. Takahara K, Kuroiwa A, Matsushima T, Nakashima Y, Takasugi M. Effects of nifedipine on platelet function. Am Hear J 1985;109:4-8.
7. Wise RA, Malamet R, Wigley FM. Acute effects of nifedipine on digital blood flow in human subjects with Raynaud's phenomenon, a double blind placebo controlled trial. J Rheumatol 1987;14:278-282.
8. 2 receptor hypersensitivity in Raynaud's phenomenon. J Vascular Med Biol 1990;2:100-106.
9. 2-adrenergic vasoconstriction in primary Raynaud's disease. Arthritis Rheum 1993;36:685-690.
10. LeRoy EC, Downey JA, Cannon PJ. Skin capilary blood flow in scleroderma. J Clin Invest 1971;50:930-939.
11. Robson P, Pearce V, Antcliff AC, et al. Double-blind trial of indoramin in digital artery disease. Br J Clin Pharmacol 1978;6:88-91.
12. Varadi DP, Lawrence AM. Suppression of Raynaud's phenomenon by methyldopa. Arch Intern Med 1969;124:13-18.
13. Russell IJ, Walsh RA. Selection of vasodilator therapy for severe Raynaud's phenomenon by sequential arterial infusion. Ann Rheum Dis 1985;44:151-154.
14. Coffman JD, Cohen RA. Intra-arterial vasodilator agents to reverse finger vasoconstriction. Clin Pharmacol Ther 1987;41:574-579.
15. Russell LJ, Lessard JA. Prazosin treatment of Raynaud's phenomenon: a double-blind single crossover study. J Rheumatol 1983;12:94-98.
16. Willerson JT, Thompson RH, Hookman P, Herdt J, Decker JL. Reserpine in Raynaud's Disease and Phenomenon. Ann Intern Med 1970;72:17-27.
17. McFadyen IJ, Housley E, Macherson AIS. Intra-arterial reserpine administration in Raynaud's syndrome. Arch Intern Med 1973;132: 526-528.
18. Prandoni AG, Moser M. Clinical appraisal of infra-arterial Priscoline therapy in the management of peripheral arterial disease. Circulation 1954;9:73-81.
19. Wollersheim H, Thien T, Fennis J, van Elteren P, van't Laar, A. Double-blind, placebo controlled study of prazosin in Raynaud's phenomenon. Clin Pharmacol Ther 40:219-225, 1986.
20. Coffman JD, Clement DL, Creager MA, et al. International study of Ketanserin in Raynaud's phenomenon. Am J Med 1989;87:264-268.
21. Warren JB, Rashpal K. Captopril increases skin microvascular blood flow secondary to bradykinin, nitric oxide, and prostaglandins. FASEB J 1995;9:411-418.
22. Tosi S, Marchesoni A, Messina K, Bellintani C, Sironi G, Faravelli C. Treatment of Raynaud's phenomenon with Captopril. Drugs Exp Clin Res 1987;13:37-42.
23. 1 infusions. J Rheumatol 1989;16:1433-1435.
24. 1 in Raynaud's syndrome. Ann Rheum Dis 1985; 44:754-760.
25. 1. Br Med J 1980;281:1031-1034.
26. 2). Br J Dermatol 1982;106:81-89.
27. Belch JJF, Drury JK, Capell H, et al. Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome. Lancet 1983;313-315.
28. Rademaker M, Cooke ED, Almond NE, et al. Comparison of intravenous infusions of iloprost and oral nifedipine in the treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomized study. Br Med J 1989;298:561-563.
29. Rademaker M, Provost TG, Beacham JA, Cooke ED, Kirby JD. Prolonged increase in digital blood flow following iloprost infusion in patients with systemic sclerosis. Postgrad Med J 1987;63:617-620.
30. McHugh NJ, Csuka M, Watson H, et al. Infusion of iloprost, a prostacyclin analogue, for treatment of Raynaud's phenomenon in systemic sclerosis. Ann Rheum Dis 1988;47:43-47.
31. Yardumian DA, Isenberg DA, Rustin M, et al. Successful treatment of Raynaud's syndrome with iloprost. A chemically stable prostacyclin analogue. Br J Rheum 1988;27:220-226.
32. Torley HI, Madhok R, Capell HA, et al. A double blind, randomized, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud's phenomenon secondary to connective tissue diseases. Ann Rheum Dis 1991;50:800-804.
33. Kyle MV, Belcher G, Hazleman BL. Placebo controlled study showing therapeutic benefit of iloprost in the treatment of Raynaud's phenomenon. J Rheumatol 1992;19:1403-1406.
34. Watson HR, Belcher G. Retrospective comparison of iloprost with other treatments for secondary Raynaud's phenomenon. Ann Rheum Dis 1991;50:359-361.
35. Wigley FM, Seibold JR, Wise RA, McCloskey DA, Dole WP. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis. J Rheumatol 1992;19:1407-1413.
36. Wigley FM, Wise RA, Seibold JR, et al. Intravenous iloprost infusion in patients with Raynaud's phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med 1994;120: 199-206.
37. 1. Br Med J 1980;281:1031.
38. Wise RA, Wigley FM. Acute effects of misoprostol on digital circulation in patients with Raynaud's phenomenon. J Rheumatol 1994;21: 80-83.
39. Belch JJF, Drury JK, Capell H, et al. Intermittent Epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome: a double-blind controlled trial. Lancet 1983;313-315.
40. Belch JJF, Newman P, Drury JK, et al. Successful treatment of Raynaud's syndrome with prostacyclin. 1981;45:255-256.
41. 2). Br J Dermatol 1982;106:81-89.
42. Lewis T, Landis EM. Some physiological effects of sympathetic ganglionectomy in human being and its effect in case of Raynaud's malady. Heart 1930;15:151-176.
43. Lewis, T. Pathological changes in arteries supplying fingers in warm-handed people and in cases of socalled Raynaud's disease. Clin Sci 1938;3:287-319.
44. Gifford RW Jr, Hines EA Jr, Winchell McK C. Sympathectomy for Raynaud's Phenomenon. Circulation 1958;28:5-13.
45. Johnston ENM, Summerly R, Birnstingl M. Prognosis in Raynaud's phenomenon after Sympathectomy. Br Med J 1964;1:962-964.
46. de Takats G, Fowler EF. Raynaud's phenomenon. JAMA 1962;179:1-8.
47. Montorsi W, Ghiringhelli C. Annoni Indications and results of the surgical treatment of Raynaud's phenomenon. J Cardiovasc Surg 1980;21:203-210.
48. de Trafford JC, Lafferty K, Potter CE, Roberts VC, Cotton LT. An epidemiological survey of Raynaud's phenomenon. Eur J Vasc Surg 1988;2:167-170.
49. Van de Wal HJ, Skotnicki SH, Wijn PF, Lacquet LK. Thoracic sympathectomy as a therapy for upper extremity ischemia. A long-term follow-up study. Thorac Cardiovasc Surg 1985;33:181-187.
50. Flatt AE. Digital arterial sympathectomy. J Hand Surg 1983;8:283-288.
51. Egloff DV, Mifsud RP, Verdan C. Superselective digital sympathectomy in Raynaud's phenomenon. Hand 1982;15:110-114.
52. Wilgis EFS. The evaluation and treatment of chronic digital ischemia. Ann Surg 1981;193: 693-698.
53. Drake DB, Kesler RVV, Morgan RF. Digital sympathectomy for refractory Raynaud's phenomenon in an adolescent. J Rheumatol 1992; 19:1286-1288.
54. O'Brien BMC, Kuman PAU, Mellow CG, Oliver TV. Radial microarteriolysis in the treatment of vasospastic disorders of the hand, especially scleroderma. J Hand Surg 1992;17b: 447-452.
55. Yee AMF, Hotchkiss RN, Pagei SA. Digital sympathectomy (DS): the treatment of choice for refractory Raynaud's phenomenon and the finger at risk. (Abstract) Arthritis Rheum 1995; 38:S335.
56. Lowell RC, Gloviczki P, Cherry KJ Jr, et al. Cervicothoracic sympathectomy for Raynaud's syndrome. Int Angiol 1993;12:168-172.
57. Goodfield MJD, Rowell NR. Treatment of peripheral gangrene due to systemic sclerosis with intravenous pentoxifylline. Clin Exp Derm 1989;14:161-162.
58. Hart DA, Fritzler MJ. Regulation of plasminogen activators and their inhibitors in rheumatic diseases: new understanding and the potential for new directions. J Rheumatol 1989;16:1184-1191.